Literature DB >> 22326468

Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.

Derrick E Fouts1, Manolito Torralba, Karen E Nelson, David A Brenner, Bernd Schnabl.   

Abstract

BACKGROUND & AIMS: Intestinal dysbiosis and bacterial translocation are common in patients with advanced liver disease, and there is strong evidence that the translocation of bacteria and their products across the epithelial barrier drives experimental liver disease progression. The aims of our study were to investigate dynamics of bacterial translocation and changes in the enteric microbiome in early stages of liver disease.
METHODS: Cholestatic liver injury was induced by ligation of the common bile duct (BDL) and toxic liver injury by injection of carbon tetrachloride (CCl(4)) in mice.
RESULTS: Increased intestinal permeability and bacterial translocation occurred one day following liver injury in both disease models. This was accompanied by decreased intestinal expression of the tight junction protein occludin. Although BDL resulted in a rapid onset of intestinal bacterial overgrowth, bacterial overgrowth was observed in mice injected with CCl(4) only in advanced stages of liver fibrosis. To further assess the qualitative changes in the intestinal microbiome, massively parallel pyrosequencing of 16S rRNA genes revealed minor microbial changes following BDL, while CCl(4) administration resulted in a relative abundance of Firmicutes and Actinobacteria compared with oil-injected mice. Four different liver disease models (cholestasis, toxic, alcohol, obesity) show few similarities in their intestinal microbiome.
CONCLUSIONS: Acute liver injury is associated with an early onset of increased intestinal permeability and bacterial translocation that precede changes in the microbiome. The enteric microbiome differs with respect to the etiology of liver disease.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326468      PMCID: PMC3357486          DOI: 10.1016/j.jhep.2012.01.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  48 in total

1.  What is the potential role of antifibrotic agents for the treatment of liver disease?

Authors:  Bernd Schnabl; David Scholten; David A Brenner
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-07-15

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents.

Authors:  Laurent Ferrier; Florian Bérard; Laurent Debrauwer; Chantal Chabo; Philippe Langella; Lionel Buéno; Jean Fioramonti
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  An obesity-associated gut microbiome with increased capacity for energy harvest.

Authors:  Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

5.  Metagenomic analysis of the human distal gut microbiome.

Authors:  Steven R Gill; Mihai Pop; Robert T Deboy; Paul B Eckburg; Peter J Turnbaugh; Buck S Samuel; Jeffrey I Gordon; David A Relman; Claire M Fraser-Liggett; Karen E Nelson
Journal:  Science       Date:  2006-06-02       Impact factor: 47.728

6.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

7.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor.

Authors:  Takeshi Inagaki; Antonio Moschetta; Youn-Kyoung Lee; Li Peng; Guixiang Zhao; Michael Downes; Ruth T Yu; John M Shelton; James A Richardson; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-10       Impact factor: 11.205

8.  Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.

Authors:  Rubén Francés; Pedro Zapater; José M González-Navajas; Carlos Muñoz; Rocío Caño; Rocío Moreu; Sonia Pascual; Pablo Bellot; Miguel Pérez-Mateo; José Such
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

Review 9.  Bacterial infection-related morbidity and mortality in cirrhosis.

Authors:  Leonidas Christou; Georgios Pappas; Matthew E Falagas
Journal:  Am J Gastroenterol       Date:  2007-05-17       Impact factor: 10.864

10.  MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection.

Authors:  Katharina Brandl; George Plitas; Bernd Schnabl; Ronald P DeMatteo; Eric G Pamer
Journal:  J Exp Med       Date:  2007-07-16       Impact factor: 14.307

View more
  121 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

2.  Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host.

Authors:  Samuel M Alaish; Alexis D Smith; Jennifer Timmons; Jose Greenspon; Daniel Eyvazzadeh; Ebony Murphy; Terez Shea-Donahue; Shana Cirimotich; Emmanuel Mongodin; Aiping Zhao; Alessio Fasano; James P Nataro; Alan Cross
Journal:  Gut Microbes       Date:  2013-04-15

Review 3.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

4.  Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Authors:  Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

Review 5.  Gut microbiota-related complications in cirrhosis.

Authors:  Isabel Gómez-Hurtado; José Such; Yolanda Sanz; Rubén Francés
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 6.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

7.  Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice.

Authors:  Xiaodong Ge; Tung-Ming Leung; Elena Arriazu; Yongke Lu; Raquel Urtasun; Brian Christensen; Maria Isabel Fiel; Satoshi Mochida; Esben S Sørensen; Natalia Nieto
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

Review 8.  Regulation of wound healing and organ fibrosis by toll-like receptors.

Authors:  Peter Huebener; Robert F Schwabe
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 9.  Linking intestinal homeostasis and liver disease.

Authors:  Bernd Schnabl
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

10.  Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice.

Authors:  Phillipp Hartmann; Michael Haimerl; Magdalena Mazagova; David A Brenner; Bernd Schnabl
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.